Screener
Xenon Pharmaceuticals XENE Total Equity
Total Equity at other companies
Other financials
Where this comes from
Reported directly by Xenon Pharmaceuticals in its filing.
Tagged under the XBRL concept us-gaap:StockholdersEquity.
The source filing: Xenon Pharmaceuticals’s 10-Q, filed August 6, 2026. Open the filing →
- Filed
- Aug 6, 2026, 4:31 PM EDT
- Fiscal quarter
- Q2 FY2026
- Calendar quarter
- Q2 2026
- Accession
- 0001193125-26-338244
FAQ
- What is Xenon Pharmaceuticals's total equity?
- Xenon Pharmaceuticals (XENE) reported total equity of $1.24B in Q2 2026.
- How has Xenon Pharmaceuticals's total equity changed year-over-year?
- Xenon Pharmaceuticals's total equity increased by 96.0% year-over-year, from $633.98M to $1.24B.
- What is the long-term trend for Xenon Pharmaceuticals's total equity?
- Over 5 years (2020 to 2025), Xenon Pharmaceuticals's total equity has grown at a 27.7% compound annual growth rate (CAGR), from $171.36M to $581.76M.
- What does total equity mean?
- Net assets attributable to shareholders — total assets minus total liabilities. Represents the book value of shareholders' ownership claim.
Ask your AI about Xenon Pharmaceuticals's total equity.
Connect your AI assistant and compare it to peers, right in your chat.
Connect your AI
Claude